PTC Therapeutics, Inc. (PTCT)
PTC Therapeutics withdraws NDA resubmission for Duchenne treatment after FDA doubts data effectiveness. This follows previous FDA rejection for Vatiquinone.
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases.
PTC Therapeutics, Inc. uses the ticker $PTCT for trading. Listed in the Stocks category within the Healthcare sectors.
Insights
- PTC Therapeutics, Inc. (PTCT) social dominance is up 246.67% from the previous month.
- PTC Therapeutics, Inc. (PTCT) engagements is up 81.42% from the previous week.
- PTC Therapeutics, Inc. (PTCT) posts created is up 137.5% from the previous week.
Price: $69.50
Price 24-Hour Time-Series Raw Data
The stock price is near its 52-week high, supported by positive analyst sentiment and increased social media activity, which are currently outweighing negative news regarding the FDA's rejection of Vatiquinone.
24-Hour: -2.11% 7-Day: -6.35% 30-Day: -4.18%
1-Year High: $86.30 on 2025-11-26
1-Year Low: $36.20 on 2025-05-06
AltRank: [---]
AltRank 24-Hour Time-Series Raw Data
PTC Therapeutics, Inc. (PTCT) is currently AltRank #866 based on combined combined social and market metrics
Daily Average: [---]
[--] Week: [-----] [----]
[--] Month: [-----] +821
[--] Months: [-----] +988
[--] Year: [-----] +375
1-Year High: [-----] on 2026-02-12
1-Year Low: [--] on 2025-09-13
Galaxy Score: [-----]
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [--]
[--] Week: [--] +1
[--] Month: [--] [---]
[--] Months: [--] [---]
[--] Year: [--] +6
1-Year High: [--] on 2025-06-23
1-Year Low: [--] on 2026-01-27
Engagements: [-----] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [-----]
[--] Week: [------] +81%
[--] Month: [------] +6.20%
[--] Months: [-------] -42%
[--] Year: [---------] +3.90%
1-Year High: [------] on 2025-07-28
1-Year Low: [---] on 2026-02-08
Engagements by network (24h): X: [---] YouTube: [--] Reddit: [--] News: [--] Instagram: [--] TikTok: [--]
Mentions: [--] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [--]
[--] Week: [--] no change
[--] Month: [---] -5.10%
[--] Months: [-----] -35%
[--] Year: [-----] +46%
1-Year High: [---] on 2025-06-30
1-Year Low: [--] on 2026-01-02
Mentions by network (24h): X: [--] YouTube: [--] Reddit: [--] News: [--] Instagram: [--] TikTok: [--]
Creators: [--] (24h)
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning PTC Therapeutics, Inc. (PTCT) in the last [--] hours which is up 5.40% from [--] in the previous [--] hours
Daily Average: [--]
[--] Week: [--] +5.10%
[--] Month: [---] +21%
[--] Months: [---] -54%
[--] Year: [-----] +68%
1-Year High: [---] on 2025-06-30
1-Year Low: [--] on 2025-10-12
The most influential creators that mention PTC Therapeutics, Inc. in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @Quantumup1 | [--] | [-----] | [--] | [---] |
| @PrometeusCT | [--] | [---] | [--] | [---] |
| @BuyTheUgly | [--] | [--] | [--] | [--] |
| @BiopharmIQ | [--] | [------] | [--] | [--] |
| @MarcJacksonLA | [--] | [-----] | [--] | [--] |
| @notdumbmoney | [--] | [---] | [--] | [--] |
Sentiment: 82%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 82%
Daily Average: 82%
[--] Week: 100% no change
[--] Month: 67% -33%
[--] Months: 67% -1%
[--] Year: 67% -18%
1-Year High: 100% on 2025-03-25
1-Year Low: 14% on 2025-04-12
Most Supportive Themes:
- Positive Analyst Ratings and Price Targets: (35%) Analysts are issuing positive ratings and price targets for PTCT, indicating potential for stock price appreciation.
- Mentions in AI and Momentum Stock Screeners: (30%) PTCT is being recognized in AI-driven stock rankings and momentum screeners, suggesting favorable technical and fundamental indicators.
- Inclusion in Biotech Stock Lists: (15%) The company is being highlighted in lists of strong biotech stocks, reflecting positive sentiment within the broader biotechnology sector.
Most Critical Themes:
- FDA Complete Response Letter for Vatiquinone: (40%) The FDA has issued a Complete Response Letter for Vatiquinone, citing insufficient efficacy, which is a significant negative development.
Social Dominance: 0.0043%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.0043%
Daily Average: 0.009%
[--] Week: 0.005% +0.00292%
[--] Month: 0.01% +0.0074%
[--] Months: 0.01% -0.011%
[--] Year: 0.01% -0.0022%
1-Year High: 0.046% on 2025-03-29
1-Year Low: 0.0019% on 2025-10-12
Market Dominance: 0.00632%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.00632%
Daily Average: 0%
1-Year High: 0.139% on 2025-04-09
1-Year Low: 0.00416% on 2025-05-06
Market Cap: $5,576,022,782
Market Cap 24-Hour Time-Series Raw Data
Current Value: $5,576,022,782
Daily Average: $4,830,510,705
[--] Week: $5,576,022,782 -6.30%
[--] Month: $5,576,022,782 -4.20%
[--] Months: $5,576,022,782 +44%
[--] Year: $5,576,022,782 +65%
1-Year High: $6,924,866,306 on 2025-11-26
1-Year Low: $2,868,311,518 on 2025-05-06
Top PTC Therapeutics, Inc. Social Posts
Top posts by engagements in the last [--] hours
Showing a maximum of [--] top social posts without a LunarCrush subscription.
"Truist reiterated $EWTX Buy-$46 and said We See Risk/Reward of 30-40% Up/20-30% Down into 4Q data $CYTK $BMY Truist added As we head into Ph2 HCM readout in 4Q we reiterate our Buy rating. As a reminder EWTX reported data from Ph2 B/C cohorts in April. While data showed favorable efficacy & LVEF excursion rates with potential to differentiate vs CMIs incidence of atrial fibrillation became a primary concern for investors. We see risk/reward of 30-40% up/20-30% down into 4Q data & note 1) Part D patient screening is key (details below); 2) KOL checks do not highlight AF as a concern; 3) In our"
X Link @Quantumup1 2025-11-03T14:39Z [----] followers, [----] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing